Lilly's R&D pipeline reveals that mazdutide is in phase 2 outside China. Meanwhile, other companies looking at combined GLP-1/glucagon agonists include Boehringer Ingelheim and Zealand Pharma ...

According to the group’s soon-to-depart chief scientific officer, Mikael Dolsten, Pfizer has a “robust pipeline” of three ... profile in the oral GLP-1 space,” he said.

Fatty liver disease linked to diabetes and obesity can easily progress to liver cirrhosis, but new research suggests that GLP ...

Fatty liver disease linked to diabetes and obesity can easily progress to liver cirrhosis, but new research suggests that GLP ...

Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

As retail investors flock to Viking Therapeutics, the biotech firm is also catching the eye of billionaire fund managers like ...

Akero Therapeutics has a solid cash runway and financial stability to support ongoing trials for its drug candidate. Read ...

Overall, recent studies have shown that GLP-1 drugs have led to a 10-20% reduction in body weight and lowered the risk of heart attack, stroke and cardiovascular death by approximately 20%.

The GLP-1 segment is a very important class of drugs ... mainly due to its solid pipeline potential, particularly its obesity drugs. The stock is also trading above its 200-day moving average ...

Most trillion-dollar companies today are in the technology sector, but one particular healthcare stock is knocking on the ...